NCT05155215Unknown1 期
A Phase 1-2 Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.0 个研究点目标入组 68 人开始时间: 2021年12月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 68
- 主要终点
- Objective response rate (ORR)
研究概览
简要总结
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult R/R Mantle Cell Lymphoma subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with relapsed or refractory mantle cell lymphoma, diagnosed as CD19 positive by cytology or histology；
- •Subjects have measurable positive lesion according to Lugano Classification;
- •≥ 18 years old;
- •Expected survival is greater than 3 months；
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- •The toxicity caused by the previous treatment has stabilized or recovered to ≤1 level (except for the case where the investigator judges that it has no clinical significance);
- •Women of childbearing age who had a negative blood pregnancy test before the start of the trial and agreed to take effective contraceptive measures during the trial period until the last follow-up; male subjects with fertility partners agreed to take effective contraceptive measures during the trial period until the last follow-up;
- •Adequate organ function;
- •Adequate vascular access for leukapheresis procedure;
- •Volunteer to participate in this trial and sign on the informed consent.
排除标准
- •Central nervous system (CNS) involvement by lymphoma;
- •Received allo-hematopoietic stem cell transplantation or organ transplantation therapy previously；
- •Subjects with cardiac atrial or cardiac ventricular lymphoma involvement；
- •Serous effusion with symptoms of compression;
- •History of autoimmune disease (eg Crohn's disease, rheumatoid arthritis, systemic lupus) within the last 2 years;
- •Presence of acute or chronic graft-versus-host disease (GVHD);
- •Use prohibited drugs or treatments within a specified period of time before cell collection；
- •Received anti-CD19 target therapy (unless the CD19 target test is still positive);
- •Received CAR-T cell therapy;
- •Received the study drug within 4 weeks before cell collection. However, if the trial treatment is invalid or the disease progresses, and at least 5 half-lives have passed before the cell collection, it is allowed to enter the group;
- •Received radiotherapy within 6 weeks prior to cell collection, including large bone marrow areas such as the sternum or pelvis. Subjects who have progressed in the radiotherapy site or have PET-positive lesions in other non-irradiated sites are eligible to be included in the group;
- •Received donor lymphocyte infusion (DLI) within 6 weeks before CAR-T cell infusion;
- •If anti-PD1, PD-L1 and other immunotherapies have been used before CAR-T cell reinfusion, at least 5 half-lives must elapse between the last medication and before CAR-T cell reinfusion;
- •History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, cerebral edema, posteriorreversible encephalopathy syndrome, or any autoimmune disease with CNS involvement;
- •Received autologous transplantation within 6 weeks before the start of screening;
- •Subjects has HBV, HCV, HIV ,EBV,ECV or syphilis infection at the time of screening;
- •Live vaccine received within 6 weeks before the start of screening;
- •History of myocardial infarction, cardiac angioplasty or stenting, unstable angina,active arrhythmias, or other clinically significant cardiac disease within 6 months of enrollment;
- •History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months of enrollment;
- •History of malignancy other than nonmelanomatous skin cancer or carcinoma in situ (eg, cervix, bladder, breast) unless disease-free for at least 3 years；
- •Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection (UTI) and bacterial pharyngitis are permitted if the investigator evaluates that it can be controlled by treatment, they can be included in the group;
- •In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.
研究组 & 干预措施
IM19 CAR-T cells
Experimental
干预措施: IM19 CAR-T cells (Biological)
IM19 CAR-T cells
Experimental
干预措施: Cyclophosphamide (Drug)
IM19 CAR-T cells
Experimental
干预措施: Fludarabine (Drug)
结局指标
主要结局
Objective response rate (ORR)
时间窗: At 3 months after IM19 CAR-T cell infusion
ORR, defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to Lugano(2014)
Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0
时间窗: Up to 28 days after IM19 CAR-T cell infusion
次要结局
- Objective response rate (ORR)(At 28 days and 6 months after IM19 CAR-T cell infusion)
- Duration of Response (DOR)(Up to 24 weeks after IM19 CAR-T cell infusion)
- Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)(Up to 24 weeks after IM19 CAR-T cell infusion)
- Progression-free survival (PFS)(Up to 24 weeks after IM19 CAR-T cell infusion)
- Overall survival (OS)(Up to 24 weeks after CAR-T cell infusion)
- Anti-therapeutic IM19 CAR-T cells antibody(Up to 24 weeks after IM19 CAR-T cell infusion)
研究者
相似试验
尚未招募
1 期
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaLeukemiaNCT05309213Beijing Immunochina Medical Science & Technology Co., Ltd.58
招募中
1 期
Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) PatientsNHLNCT04440436Beijing Immunochina Medical Science & Technology Co., Ltd.52
进行中（未招募）
1 期
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, Adult B-CellNCT03984968The First Affiliated Hospital of Soochow University40
招募中
1 期
CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALLCD19+ Relapse/Refractory B-ALLNCT05270772Chinese PLA General Hospital9
Unknown
1 期
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell MalignanciesB Cell LymphomaAcute Lymphoblastic LeukemiaNCT03366350Wuhan Sian Medical Technology Co., Ltd50